Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
The stock exceeded the S&P 500, which registered a loss of 0.2% for the day. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%. Shares of the drugmaker witnessed a loss of 7.12% over the previous month, trailing the performance of the Medical sector with its gain of 2.21% and the S&P 500's gain of 3.32%. Market participants will be closely following the financial results of Ligand Pharmaceuticals in its upcoming release. The company is forecasted to report an EPS of $1.07, showcasing a 53.07% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $32.5 million, showing a 26.1% drop compared to the year-ago quarter. LGND's full-year Zacks Consensus Estimates are calling for earnings of $4.42 per share and revenue of $139.25 million. These results would represent year-over-year changes of +8.87% and +6.04%, respectively. Investors might also notice rece
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand and Agenus Enter Into $100 Million Royalty Financing AgreementBusiness Wire
- Don't Overlook These Top Medical Stocks as Q1 Earnings Approach [Yahoo! Finance]Yahoo! Finance
- Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio [Seeking Alpha]Seeking Alpha
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024Business Wire
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.MarketBeat
LGND
Earnings
- 2/27/24 - Beat
LGND
Sec Filings
- 5/7/24 - Form 8-K
- 5/2/24 - Form 4
- 4/26/24 - Form 4
- LGND's page on the SEC website